Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Unresectable or Metastatic Breast Cancer
Interventions: DRUG: HRS-8080; Dalpiciclib Isethionate Tablets
Sponsor: Shandong Suncadia Medicine Co., Ltd.